Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for diagnosing and treating various diseases. The company reported selling, general, and administrative expenses of $157,565,000.00 indicating its operational overhead costs. The operating expenses amount to $269,426,000.00 encompassing various operational costs incurred. With an operating income ratio of -0.91 the company's operational profitability margin is understood in the context of its overall financial health. Additionally, the EBITDA ratio is -0.72 highlighting the company's operational efficiency and its ability to generate earnings before interest, taxes, depreciation, and amortization. Furthermore, the company reported depreciation and amortization expenses of $19,256,000.00 reflecting the wear and tear of its assets in its financial statements. Adaptive Biotechnologies continues to innovate with products such as immunoSEQ and clonoSEQ which serve critical roles in the life sciences research and clinical diagnostics sectors, and its operational effectiveness is vital for its sustained development. The stock is affordable at $8.84 suitable for budget-conscious investors looking for opportunities in the market. The stock has a high average trading volume of 2,308,015.00 indicating strong liquidity that can attract a diverse range of investors. With a market capitalization of $1,356,618,810.00 the company is classified as a small-cap player, a designation that often entails a dynamic growth profile. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape through its innovative immune medicine platform. Additionally, it belongs to the Healthcare sector, driving innovation and growth in the field of health and biotechnology. As it continues to expand its offerings and collaborations with entities like Genentech and Microsoft, Adaptive Biotechnologies positions itself strategically for future advancements in disease diagnostics and treatment options.